Table 3.
Univariate and multivariate analysis of prognostic factors for cancer-specific survival of metastatic RCC patients treated by nivolumab monotherapy.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (<66 vs. ≥66 years) | 1.33 | 0.36–4.99 | 0.670 | |||
| Gender (Male vs. Female) | 1.98 | 0.49–8.07 | 0.341 | |||
| WHO/ISUP grade (1, 2 vs. 3, 4) | 13.9 | 1.64–117.4 | 0.016 | 22.49 | 1.44–350.4 | 0.026 |
| Coagulative necrosis (absence vs. presence) | 1.39 | 0.37–5.27 | 0.630 | |||
|
MSKCC risk classification (Good/Intermediate vs. Poor) |
14.8 | 2.97–73.66 | 0.001 | 21.14 | 2.41–185.2 | 0.006 |
| Number of prior therapies (1 vs. ≥2) | 0.52 | 0.14–1.98 | 0.338 | |||
| NLR (<3.45 vs. ≥3.45) | 3.05 | 0.75–12.36 | 0.119 | |||
| PLR (<1.61 vs. ≥1.61) | 1.88 | 0.47–7.52 | 0.374 | |||
| CRP (<1 mg/dL vs. ≥1 mg/dL) | 2.79 | 0.68–11.41 | 0.153 | |||
Abbreviations: RCC = renal cell carcinoma, HR = hazard ratio, CI = confidence interval, MSKCC = Memorial Sloan Kettering Cancer Center, NLR = neutrophil to lymphocyte ratio, PLR = platelet to lymphocyte ratio, CRP = C reactive protein.